VIVEbiotech shares insights in GEN
Natalia Elizalde highlights the complementary roles of ex vivo and in vivo approaches in improving patient access to advanced therapies.
VIVEbiotech is featured in a recent article published by GEN examining the innovations that are helping make CAR-T therapies more scalable, accessible, and sustainable.
The article brings together perspectives from experts at VIVEbiotech, Terumo Blood and Cell Technologies, and Bracco, who discuss how advances in manufacturing, automation, and vector technologies will be essential to expanding patient access as CAR-T therapies continue to evolve.
Representing VIVEbiotech, Natalia Elizalde, PhD, Chief Business Development Officer, highlights the complementary roles of ex vivo and in vivo approaches. She emphasizes that future progress will not be driven by a single technology, but by the ability of different platforms to address unmet patient needs while improving scalability and accessibility.
The article also explores how automation, integrated manufacturing workflows, and process innovation can help overcome some of the key challenges facing CAR-T manufacturing today.
VIVEbiotech is proud to contribute to industry discussions that help shape the future of advanced therapies and expand access to life-changing treatments for patients worldwide.
